[go: up one dir, main page]

AU2001296229A1 - Methods of using a human il-17-related polypeptide to treat disease - Google Patents

Methods of using a human il-17-related polypeptide to treat disease

Info

Publication number
AU2001296229A1
AU2001296229A1 AU2001296229A AU9622901A AU2001296229A1 AU 2001296229 A1 AU2001296229 A1 AU 2001296229A1 AU 2001296229 A AU2001296229 A AU 2001296229A AU 9622901 A AU9622901 A AU 9622901A AU 2001296229 A1 AU2001296229 A1 AU 2001296229A1
Authority
AU
Australia
Prior art keywords
human
methods
related polypeptide
treat disease
immunodeficiencies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296229A
Inventor
Andrew Lawrence Glasebrook
Ling Liu
Christy Michelle Newton
Jonathan Wendell Tetreault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001296229(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001296229A1 publication Critical patent/AU2001296229A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Methods are provided for the treatment or prevention of atherosclerosis, allergic autoimmune diseases, endothelial cell apoptosis, allograft vasculopathy, hypertension, congestive heart failure, ischemia/reperfusion injury, type 1 diabetes, inflammation, immunodeficiencies, cancers, and infectious diseases by administering a human IL-17 related polypeptide and/or an antibody recognizing an epitope thereof to a patient in need of such therapy.
AU2001296229A 2000-10-13 2001-09-28 Methods of using a human il-17-related polypeptide to treat disease Abandoned AU2001296229A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24017700P 2000-10-13 2000-10-13
US60/240,177 2000-10-13
US30993601P 2001-08-03 2001-08-03
US60/309,936 2001-08-03
PCT/US2001/027737 WO2002033083A2 (en) 2000-10-13 2001-09-28 Methods of using a human il-17-related polypeptide to treat disease

Publications (1)

Publication Number Publication Date
AU2001296229A1 true AU2001296229A1 (en) 2002-04-29

Family

ID=26933217

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296229A Abandoned AU2001296229A1 (en) 2000-10-13 2001-09-28 Methods of using a human il-17-related polypeptide to treat disease

Country Status (7)

Country Link
US (1) US20060083713A1 (en)
EP (1) EP1326974B1 (en)
AT (1) ATE349523T1 (en)
AU (1) AU2001296229A1 (en)
DE (1) DE60125563T2 (en)
ES (1) ES2277947T3 (en)
WO (1) WO2002033083A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1076703E (en) 1998-05-15 2007-10-10 Genentech Inc Therapeutic uses of il-17 homologous polypeptides
EP3112468A1 (en) * 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2003251900B2 (en) * 2002-07-15 2008-12-18 President And Fellows Of Harvard College Methods and compositions for modulating T helper (Th) cell development and function
MX341074B (en) 2003-07-08 2016-08-05 Genentech Inc HETEROLOGY POLYPEPTIDES IL-17 A / F AND THERAPEUTIC USES OF THE SAME.
JP2007506789A (en) * 2003-09-25 2007-03-22 ザイモジェネティクス， インコーポレイテッド Method for treating autoimmune disease using IL-21
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
EP1671642A1 (en) * 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
JP2010531888A (en) * 2007-06-26 2010-09-30 レクシコン ファーマシューティカルズ インコーポレイテッド Methods for treating serotonin-mediated diseases and disorders
NZ588674A (en) 2008-05-05 2013-02-22 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
US20120076754A1 (en) * 2009-05-20 2012-03-29 Ziad Mallat Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis
US20130064788A1 (en) * 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
WO2017007960A1 (en) * 2015-07-07 2017-01-12 Fred Hutchinson Cancer Research Center Compositions, kits, and methods using interleukin-17c to promote neural growth and/or neural survival
JP7186094B2 (en) 2016-05-06 2022-12-08 イグジキュア オペレーティング カンパニー Liposomal Spherical Nucleic Acid (SNA) Constructs Presenting Antisense Oligonucleotides (ASOs) for Specific Knockdown of Interleukin 17 Receptor mRNA
CN106153923B (en) * 2016-06-21 2017-12-05 北京大学第一医院 Predict that glutamic-pyruvic transaminase is less than the system of the Patients with Chronic Hepatitis B inflammation degree of two times of normal upper limits
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1076703E (en) * 1998-05-15 2007-10-10 Genentech Inc Therapeutic uses of il-17 homologous polypeptides
CA2329274A1 (en) * 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
AU6277799A (en) * 1998-10-02 2000-04-26 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
EP1240325B1 (en) * 1999-12-23 2009-09-30 Genentech, Inc. Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
EP1255837A2 (en) * 2000-02-08 2002-11-13 Amgen Inc. Il-17 like molecules and uses thereof
WO2002008285A2 (en) * 2000-06-22 2002-01-31 Amgen, Inc. Il-17 molecules and uses thereof
EP1806404B1 (en) * 2000-07-27 2010-08-18 Wyeth LLC Use of IL-10 receptor beta antagonistic antibodies for inhibiting IL-TIF/IL-21 induction of acute phase proteins

Also Published As

Publication number Publication date
ATE349523T1 (en) 2007-01-15
US20060083713A1 (en) 2006-04-20
EP1326974A2 (en) 2003-07-16
EP1326974B1 (en) 2006-12-27
WO2002033083A3 (en) 2003-03-06
WO2002033083A2 (en) 2002-04-25
ES2277947T3 (en) 2007-08-01
DE60125563D1 (en) 2007-02-08
DE60125563T2 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
AU2001296229A1 (en) Methods of using a human il-17-related polypeptide to treat disease
MXPA05013564A (en) Fusion proteins.
MX338122B (en) Therapeutic epitopes and uses thereof.
EA200101250A1 (en) PREVENTION AND THERAPY OF AMYLOIDOGENIC DISEASE
FI956014A0 (en) Use of non- and decapeptides in the manufacture of a medicament for the treatment of AIDS
AU2002233288A1 (en) Combined use of Enzyme Inhibitors and Pharmaceutical Preparations thereof for the Treatment and Prophylaxis of Arteriosclerosis, for the Treatment and Prevention of Allergic Reactions of Type I According to the Gell and Coombs Classification, and for the Treatment and Prevention of Dermatological Diseases Associated with FO
BRPI0410684A (en) Use of a protein-conjugated peptide that acts as an immunogen for the production of antibodies capable of specifically recognizing any of the predominant variants of the α40 and α42 amyloid beta peptide in the preparation of a medicament for the prevention and / or treatment of a disease. and use of an antibody or an active fragment or derivative of an antibody that specifically recognizes any of the predominant amyloid beta peptide variants, aß40 and aß42, in the preparation of a medicament for preventing and / or treating a disease.
DK1151009T3 (en) Antimicrobial / endotoxin neutralizing polypeptide
EP1706423B8 (en) Therapeutic and diagnostic anti-hsp 70 antibodies
FI953565A7 (en) New anticoagulant cofactor activity
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
WO2023081194A3 (en) Methods for treating alzheimer's disease
ATE342716T1 (en) USE OF CARBOXY COMPOUNDS SUCH AS 2(4-ACETOXYPHENYL)-2-CHLORO-N-METHYL-ETHYLAMMONIUM CHLORIDE AS ANTI-INFLAMMATORY AGENTS
WO2001036656A3 (en) A complex between hyaluronic acid and a biomolecule and its use
MXPA02011533A (en) NOVEL FORMULATIONS OF agr; 2, 4 DISULFOPHENYL N TERT BUTYLNITRONE.
HUP0400340A2 (en) Methods for reducing immunogenicity of polypeptides
NO20044698L (en) Statin therapy to increase cognitive maintenance
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
ATE404519T1 (en) HYPERFORINE DERIVATIVES, THEIR USE AND PREPARATIONS CONTAINING THEM
ATE293445T1 (en) PRODUCTION OF PURE STEREOISOMERS OF TRICYCLO-(5.2.1.0(2.6))-DEC-9-YL-XANTHOGENATE AND THEIR USE AS MEDICINAL PRODUCTS
WO2002026258A3 (en) Treatment of immune-mediated diseases by oral administration of plasma fractions
EA199800941A1 (en) THERAPEUTICALLY MEANS CONTAINING OXYGEN ANION-RADICALS AND / OR PRODUCTS OF THEIR SUBSEQUENTAL TURNING AND DIVISION AND THEIR APPLICATION FOR THE TREATMENT OF PARKINSON'S DISEASE
WO2002048175A3 (en) Mhc class i associated peptides for prevention and treatment of tuberculosis
WO2001075021A3 (en) A novel polypeptide, glucose transport-associated human protein 10 and the polynucleotide encoding the polypeptide
WO2001079439A3 (en) A novel polypeptide, a human cannabinoid receptor protein 19 and the polynucleotide encoding the polypeptide